Shares of Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $3.45 and traded as low as $2.17. Moleculin Biotech shares last traded at $2.44, with a volume of 77,274 shares trading hands.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on shares of Moleculin Biotech in a research note on Saturday. They set a “sell” rating on the stock.
Get Our Latest Stock Report on MBRX
Moleculin Biotech Stock Up 9.4 %
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Moleculin Biotech stock. Armistice Capital LLC bought a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned about 9.60% of Moleculin Biotech at the end of the most recent quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
See Also
- Five stocks we like better than Moleculin Biotech
- The 3 Best Retail Stocks to Shop for in August
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Health Care Stocks Explained: Why You Might Want to Invest
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to buy stock: A step-by-step guide for beginnersÂ
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.